PD-1/PD-L1 inhibitor Clinical Trials

3 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 1Phase 4: 1

Top Sponsors

Shanghai Pulmonary Hospital, Shanghai, China1
Peking University1
Peking Union Medical College Hospital1

Indications

Cancer3
Biliary Tract Cancer (BTC)1
NSCLC (Non-small Cell Lung Cancer)1
Biliary Tract Cancer1
Lung Cancer1

Other3 trials

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Phase 2

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

N/A

Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.